全文获取类型
收费全文 | 10152篇 |
免费 | 388篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 145篇 |
儿科学 | 199篇 |
妇产科学 | 86篇 |
基础医学 | 1313篇 |
口腔科学 | 130篇 |
临床医学 | 740篇 |
内科学 | 2473篇 |
皮肤病学 | 93篇 |
神经病学 | 711篇 |
特种医学 | 487篇 |
外科学 | 1839篇 |
综合类 | 33篇 |
预防医学 | 279篇 |
眼科学 | 330篇 |
药学 | 655篇 |
中国医学 | 28篇 |
肿瘤学 | 1061篇 |
出版年
2023年 | 37篇 |
2022年 | 86篇 |
2021年 | 139篇 |
2020年 | 61篇 |
2019年 | 93篇 |
2018年 | 136篇 |
2017年 | 117篇 |
2016年 | 151篇 |
2015年 | 151篇 |
2014年 | 220篇 |
2013年 | 327篇 |
2012年 | 512篇 |
2011年 | 622篇 |
2010年 | 357篇 |
2009年 | 346篇 |
2008年 | 617篇 |
2007年 | 686篇 |
2006年 | 655篇 |
2005年 | 684篇 |
2004年 | 754篇 |
2003年 | 734篇 |
2002年 | 725篇 |
2001年 | 158篇 |
2000年 | 161篇 |
1999年 | 150篇 |
1998年 | 175篇 |
1997年 | 142篇 |
1996年 | 129篇 |
1995年 | 120篇 |
1994年 | 101篇 |
1993年 | 113篇 |
1992年 | 101篇 |
1991年 | 90篇 |
1990年 | 85篇 |
1989年 | 90篇 |
1988年 | 84篇 |
1987年 | 68篇 |
1986年 | 67篇 |
1985年 | 69篇 |
1984年 | 59篇 |
1983年 | 38篇 |
1982年 | 39篇 |
1981年 | 35篇 |
1980年 | 43篇 |
1979年 | 50篇 |
1978年 | 33篇 |
1977年 | 27篇 |
1973年 | 16篇 |
1971年 | 21篇 |
1966年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Seiitsu Ono Takashi Imai Shigeru Munakata Keiichi Takahashi Fumio Kanda Kazuki Hashimoto Takahiko Yamano Natsue Shimizu Koichi Nagao Mitsuo Yamauchi 《Journal of the neurological sciences》1998,160(2):565-147
During the last 10 years, we have demonstrated morphological and biochemical abnormalities of skin extracellular matrices in amyotrophic lateral sclerosis (ALS). However, currently little is known concerning collagen of the spinal cord in ALS. We measured the amount of collagen and characterized collagen at light and electron microscopic levels in posterior funiculus, posterior half of lateral funiculus and anterior horn of cervical enlargement of the spinal cord obtained from ten patients with ALS, 11 patients with other neurologic diseases (control group A), and ten patients without neurologic ones (control group B). In posterior half of lateral funiculus and anterior horn, (1) by light microscopy, there was no significant difference in vessel wall area between ALS patients and control groups A and B; (2) ultrastructurally, collagen bundles were more fragmented and widely separated, and the fibrils were randomly oriented in the perivascular space of capillaries in ALS patients, which were not observed in any areas of control groups or in posterior funiculus of ALS patients; and (3) the collagen contents in ALS were significantly lower (P<0.001 and P<0.001, respectively) than those in control groups A and B. Fragmented and widely separated collagen bundles in the interstitial tissue surrounding capillaries and markedly decreased amount of collagen in posterior half of lateral funiculus and in anterior horn of ALS could be related to the degeneration of the upper and lower motor neurons in the spinal cord in ALS, that is, selective neuronal vulnerability in ALS. 相似文献
42.
M Kuwahara K Kambe S Kurosu S Kageyama N Ioritani S Orikasa K Takayama 《The Journal of urology》1987,137(5):837-840
Extracorporeal stone disintegration using a chemical explosive (10 mg. lead azide) as an energy source of underwater shock waves was performed in 105 patients 11 to 72 years old who had stones in the upper urinary tract. We used a prototype disintegrator in this series. The over-all rate free of stones 3 months after treatment was 82 per cent. Shock wave therapy was performed alone in 77 patients (73 per cent), while the remainder required combined treatment with percutaneous and/or transurethral lithotripsy. The most common complications were colic pain (30 per cent) and fever (23 per cent). In 4 patients other complications, that is bacteremia, gastrointestinal bleeding, ureteral injury and subcapsular renal hematoma, were observed but they were treated conservatively with no serious adverse effects. Our study demonstrates the safe use of this method for clinical treatment. 相似文献
43.
Hajime ISOMOTO Yohei MIZUTA Keiichiro MATSUNAGA Michio TOMONAGA Isao SHIMOKAWA Katsuhisa OMAGARI Fuminao TAKESHIMA Kunihiko MURASE Shigeru KOHNO 《Digestive endoscopy》1998,10(2):135-141
Abstract: We report a case of glucagonoma syndrome with liver metastasis, who responded completely to dacarbazine chemotherapy. A 77-year-old woman complained of itching skin eruptions (diagnosed as necrolytic migratory erythema) and weight loss. She was found to have glucose intolerance, anemia, hypoproteinemia and hyperglucagonemia. Abdominal CT and celiac arteriography showed a hypervascular tumor in the pancreatic tail and a metastatic tumor in the left hepatic lobe. Immunohistochemical examination of the metastatic liver tumor obtained by laparoscopic biopsy revealed the tumor cells to be positive for glucagon. The patient was treated with 20 courses of 300 mg/day intravenous dacarbazine for 5 consecutive days followed by a 4 week drug-free interval. No major side effects were noted. Treatment resulted in disappearance of the skin lesions and correction of anemia, glucose intolerance, hypoproteinemia and hyperglucagonemia. Follow-up abdominal CT showed complete resolution of both the primary pancreatic tumor and the metastatic liver tumor. We suggest that dacarbazine be considered as the treatment of choice for metastatic glucagonoma. 相似文献
44.
Shiro Nakaike Takehiro Yamagishi Kazunori Samata Keiko Nishida Kouko Inazuki Tomoko Ichihara Yoshihiro Migita Susumu Otomo Hironaka Aihara Shigeru Tsukagoshi 《Cancer chemotherapy and pharmacology》1989,23(3):135-139
Summary A novel antitumor compound, N--dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]-phenazine-6-carboxamide sodium salt (NC-190) was evaluated for its antitumor activity in experimental murine tumor systems. In the initial studies with P388 leukemia (i.p.-i.p.), NC-190 led to an increase of >200% in life span (ILS), and 75% of the mice were alive on day 30, when the optimal dose (50 mg/kg, days 1–5) was given. Additionally, the compound had significant activities against i.p. inoculated mouse L1210 leukemia, B16 melanoma, M5076 reticulum cell sarcoma, sarcoma 180, mouse hepatoma MH134, and rat Yoshida sarcoma and Yoshida ascites hepatoma AH130. The optimal dose resulted in a >280% ILS with a 30-day survival of 50% in mice with L1210 leukemia (100 mg/kg, days 1–5), a 156% ILS in mice with B16 melanoma (50 mg/kg, days 1–5), a 98% ILS with a 90-day survival of 25% in mice with M5076 reticulum cell sarcoma (25 mg/kg, days 1, 5, 9, and 13), a >300% ILS with a 60-day survival of 50% in mice with sarcoma 180 (50 mg/kg, days 3–10), a 148% ILS with a 60-day survival of 25% in mice with MH134 (25 mg/kg, days 1–5), a 129% ILS with a 60-day survival of 12.5% in rats with Yoshida sarcoma (12.5 mg/kg, day 3–10), and a >161% ILS with a 60-day survival of 50% in rats with AH130 (6.3 mg/kg, days 3–10). In the experiments with s.c. inoculated tumors, NC-190 not only inhibited tumor growth, but also increased the life span of mice with Lewis lung carcinoma or B16 melanoma. The 60-day survivors accounted for 60% and 30% in mice with Lewis lung carcinoma and B16 melanoma, respectively. The compound significantly inhibited the spontaneous lung metastasis of Lewis lung carcinoma by more than 90% when eight daily i.v. injections were given. NC-190 was active by the i.p., s.c., and i.v. routes. Five consecutive daily i.p. doses (days 1–5) were more effective than a single dose (day 1), two doses (days 1 and 5), or three doses (days 1, 5, and 9). NC-190 warrants further study as a potential antineoplastic agent against human neoplasms, as it has a broad spectrum of antitumor activity and inhibits metastasis.Abbreviations
ILS
increase in life span
-
MST
median survival time
-
MMC
mitomycin C
-
ADM
adriamycin
-
CPA
cyclophosphamide
-
5-FU
5-fluorouracil 相似文献
45.
Suzuki Hisamitsu; Ota Kazuo; Ohno Ryuzo; Masaoka Toru; Shibata Hirotoshi; Kimura Ikuro; Amaki Ichita; Miura Yasusada; Uzuka Yoshiro; Kawato Masafumi; Shirakawa Shigeru; Hirota Yutaka; Maekawa Tadashi; lmai Kuniyuki; Takaku Fumimaro; Shimoyama Masanori; Kitahara Takeshi; Oguro Masao; Kozuru Mitsuo; Kawagoe Hiroya; Nakamura Toru; Yamada Kazumasa 《Japanese journal of clinical oncology》1989,19(4):338-347
Patients with acute (2,569) and chronic (957) leukemia diagnosedat 19 institutes took part in the study on the "MultidisciplinaryTreatment of Leukemia" between 1971 and 1985 and were investigatedretrospectively. By dividing the 15 years into three five-yearperiods, we were able to compare patient ratios in the differentperiods. The proportions of acute to chronic leukemia casesshowed no obvious change; however, the proportions of casesdiagnosed as acute lymphocytic leukemia in acute leukemia showeda significant increase. The main chemotherapeutic drugs usedduring the three time periods were cytarabine or its analogues,the anthracyclines, 6-mercaputopurine and prednisolone, againstacute myelogenous leukemia, and the vinca alkaloids, prednisoloneand the anthracyclines against acute lymphocytic leukemia. Therate of complete remission from acute myelogenous leukemia mademarked progress, from 45.1% during 19711975 to 62.3%during 19811985, but that of acute lymphocytic leukemiashowed no significant progress, being 65% during 19711975and 69.7% during 19811985. The durations of remission,however, and the survival times for patients with acute lymphocyticleukemia, as well as for those with acute myelogenous leukemia,became significantly longer over the three periods. Median survivaltimes from chronic myelocytic leukemia were 3740 mo inall three periods, showing no progress. There was a better prognosisin cases of chronic myelocytic leukemia with, than without,Philadelphia chromosome. Except for a low incidence of chroniclymphocytic leukemia in Japan, adult leukemia patients' characteristicsand prognoses seem to be almost the same in Japan as in theU.S.A. and Europe. 相似文献
46.
Gao HZ Kobayashi K Tabata A Tsuge H Iijima M Yasuda T Kalkanoglu HS Dursun A Tokatli A Coskun T Trefz FK Skladal D Mandel H Seidel J Kodama S Shirane S Ichida T Makino S Yoshino M Kang JH Mizuguchi M Barshop BA Fuchinoue S Seneca S Zeesman S Knerr I Rodés M Wasant P Yoshida I De Meirleir L Abdul Jalil M Begum L Horiuchi M Katunuma N Nakagawa S Saheki T 《Human mutation》2003,22(1):24-34
Classical citrullinemia (CTLN1), a rare autosomal recessive disorder, is caused by mutations of the argininosuccinate synthetase (ASS) gene, localized on chromosome 9q34.1. ASS functions as a rate-limiting enzyme in the urea cycle. Previously, we identified 32 mutations in the ASS gene of CTLN1 patients mainly in Japan and the United States, and to date 34 different mutations have been described in 50 families worldwide. In the present study, we report ASS mutations detected in 35 additional CTLN1 families from 11 countries. By analyzing the entire coding sequence and the intron-exon boundaries of the ASS gene using RT-PCR and/or genomic DNA-PCR, we have identified 16 novel mutations (two different 1-bp deletions, a 67-bp insertion, and 13 missense) and have detected 12 known mutations. Altogether, 50 different mutations (seven deletion, three splice site, one duplication, two nonsense, and 37 missense) in 85 CTLN1 families were identified. On the basis of primary sequence comparisons with the crystal structure of E. coli ASS protein, it may be concluded that any of the 37 missense mutations found at 30 different positions led to structural and functional impairments of the human ASS protein. It has been found that three mutations are particularly frequent: IVS6-2A>G in 23 families (Japan: 20 and Korea: three), G390R in 18 families (Turkey: six, U.S.: five, Spain: three, Israel: one, Austria: one, Canada: one, and Bolivia: one), and R304W in 10 families (Japan: nine and Turkey: one). Most mutations of the ASS gene are "private" and are distributed throughout the gene, except for exons 5 and 12-14. It seems that the clinical course of the patients with truncated mutations or the G390R mutation is early-onset/severe. The phenotype of the patients with certain missense mutations (G362V or W179R) is more late-onset/mild. Eight patients with R86H, A118T, R265H, or K310R mutations were adult/late-onset and four of them showed severe symptoms during pregnancy or postpartum. However, it is still difficult to prove the genotype-phenotype correlation, because many patients were compound heterozygotes (with two different mutations), lived in different environments at the time of diagnosis, and/or had several treatment regimes or various knowledge of the disease. 相似文献
47.
Koichiro Yuji Shigesaburo Miyakoshi Daisuke Kato Yuji Miura Tomohiro Myojo Naoko Murashige Yukiko Kishi Kazuhiro Kobayashi Eiji Kusumi Hiroto Narimatsu Tamae Hamaki Tomoko Matsumura Masahiro Kami Takahiro Fukuda Shigeru Masuo Kazuhiro Masuoka Atsushi Wake Junichi Ueyama Akiko Yoneyama Ko Miyamoto Haruhisa Nagoshi Michio Matsuzaki Shinichi Morinaga Yoshitomo Muto Yoichi Takeue Shuichi Taniguchi 《Biology of blood and marrow transplantation》2005,11(4):314-318
We report the results of reduced-intensity unrelated cord blood transplantation (RI-UCBT) in patients with advanced malignant lymphoma. Twenty patients (median age, 46.5 years; range, 27-66 years) underwent RI-UCBT with a preparative regimen consisting of fludarabine 125 mg/m2 , melphalan 80 mg/m 2 , and 4 Gy of total body irradiation. The median infused total cell dose was 2.75 x 10(7)/kg (range, 2.3-3.4 x 10(7)/kg). Graft-versus-host disease (GVHD) prophylaxis was composed of cyclosporine or tacrolimus alone. Fifteen patients achieved primary neutrophil engraftment after a median of 20 days. Eight patients developed grade II to IV acute GVHD, and 2 developed chronic GVHD. Of the 16 patients with evaluable disease, 10 achieved a complete response. Primary disease recurred in 1 patient, and transplant-related mortality within 100 days occurred in 8 of 20 patients. The estimated 1-year probability of progression-free survival was 50%. These data suggest that RI-UCBT is a feasible option for patients with refractory lymphoma who lack an HLA-matched donor. 相似文献
48.
49.
50.
Miwa N Hayakawa S Miyazaki S Myojo S Sasaki Y Sakai M Takikawa O Saito S 《Molecular human reproduction》2005,11(12):865-870
Recent data demonstrated that CD4+CD25+ regulatory T (Treg) cells and an enzyme called indoleamine 2,3-dioxygenase (IDO) mediate maternal tolerance to the fetus. Interestingly, Treg cells express the CTLA-4 molecule on their surface, and B7 (CD80/86) ligation by CTLA-4 enhanced IDO activity of dendritic cells (DCs) and monocytes by the induction of interferon gamma (IFN-gamma) production. In this study, we studied the IDO expression on peripheral blood monocytes and decidual monocytes or DCs after treatment with CTLA-4/Fc fusion protein or IFN-gamma using flow cytometry. IDO expressions on both peripheral blood DC and decidual DC and monocytes were up-regulated during normal pregnancy. On the other hand, both IDO expression on DC and monocytes after IFN-gamma treatment or CTLA-4 treatment were decreased in spontaneous abortion cases. The expression of CD86 on peripheral blood and decidual monocytes and DC in spontaneous abortion cases was lower compared with those in normal pregnancy subjects. Also, IFN-gamma production by decidual and peripheral blood mononuclear cells after CTLA-4/Fc treatment in spontaneous abortion cases was significantly lower than those in normal pregnancy subjects. These data suggest that CTLA-4 on Treg cells up-regulates IDO expression on decidual and peripheral blood DC and monocytes by the induction of IFN-gamma production. 相似文献